zbio: the income statement

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Total revenue	-	0	10,000	-
Research and development	34,402	43,027	34,915	33,530
General and administrative	13,178	12,136	12,415	7,454
Acquired in-process research and development	5,000	-	-	-
Total operating expenses	52,580	55,163	47,330	40,984
Loss from operations	-52,580	-55,163	-37,330	-40,984
Other income, net	1,081	2,960	3,552	2,378
Total other income (expense), net	1,081	2,960	3,552	2,378
Loss before income taxes	-51,499	-52,203	-33,778	-
Income tax (provision) benefit	-	20	-205	-
Net loss to common stockholders	-51,499	-52,223	-33,573	-38,606
Unrealized gain on investments	35	30	12	-
Foreign currency translation adjustment	-10	-265	-65	-50
Comprehensive loss	-51,474	-52,458	-33,626	-38,656

Earnings per share, basic	-1.22	-1.25	-0.8	-5.02
Earnings per share, diluted	-1.22	-1.25	-0.8	-5.02
Weighted average number of shares outstanding, basic	42,159,340	41,865,400	41,800,802	7,697,695
Weighted average number of shares outstanding, diluted	42,159,340	41,865,400	41,800,802	7,697,695